The genetic polymorphism of metalloproteinases MMP2, 7, 9 and MMP inhibitor TIMP2 in sarcoidosis Source: Annual Congress 2011 - Genetic and molecular background in pulmonary fibrosis Year: 2011
The role of genetic polymorphisms of glutation-S-transferase μ1 (GSTM1) and gelatinase B (MMP9) in the risk of COPD development Source: Annual Congress 2003 - Alpha-1 antitrypsin deficiency and COPD Year: 2003
The role of matrix metalloproteinase- 9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMMP-1) in sarcoidosis and idiopathic pulmonary fibrosis. Correlation with echocardiography Source: Eur Respir J 2006; 28: Suppl. 50, 745s Year: 2006
Associations of an intron MMP9 polymorphism and the serum levels of gelatinase B with the development of COPD Source: International Congress 2019 – New molecular signatures in COPD, lung cancer and a1-antitrypsin deficiency Year: 2019
Matrix metalloproteinases and tissue inhibitor of metalloproteinase-1 in sarcoidosis and IPF Source: Eur Respir J 2002; 20: 1220-1227 Year: 2002
Genetic polymorphisms in MMP9 and TIMP2 genes and risk of chronic obstructive pulmonary disease Source: Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer Year: 2009
Effects of keratinocyte growth factor (KGF) on matrix metalloproteinases (MMPs) & tissue inhibitors of metalloproteinases (TIMPs) mRNA levels in emphysematous rats lungs Source: Annual Congress 2008 - Inflammatory trigger mechanisms in asthma and COPD Year: 2008
Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients Source: Eur Respir J 2005; 25: 885-890 Year: 2005
Proteins involved in extracellular matrix dynamics are associated with respiratory syncytial virus disease severity Source: Eur Respir J 2012; 39: 1475-1481 Year: 2012
Genes affecting mRNA stability and metalloproteinase inhibitor RECK are down-regulated in patients with COPD Source: Annual Congress 2013 –New insights into epigenetic mechanisms in the lung Year: 2013
Are there serum levels of MMP-2 and MMP-9 may be markers of COPD phenotypes? Source: Annual Congress 2012 - COPD treatment and varia Year: 2012
The promoter polymorphism -1562C/T in matrix metalloproteinase-9 and COPD severity Source: Eur Respir Rev 2006; 15: 230-232 Year: 2006
The promoter polymorphism -1562C/T in matrix metalloproteinase-9 and COPD severity Source: Eur Respir J 2006; 28: Suppl. 50, 825s Year: 2006
Association of TNF, IL8, NOS1, NOS3 and NRAMP1 gene polymorphisms with COPD exacerbation etiology Source: Eur Respir J 2005; 26: Suppl. 49, 95s Year: 2005
Neutrophil elastase gene expression and relation with lung function in Alpha-1 Antitrypsin deficiency patients. Source: International Congress 2017 – Current molecular and genetic understanding of lung diseases Year: 2017
Human macrophage elastase (MMP-12) expression in human emphysematous lungs: role in extracellular matrix remodelling in chronic obstructive pulmonary diseases (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 501s Year: 2001
Expression of matrix metalloproteinases and TIMP inhibitors in circulation/lung in patients with chronic obstructive pulmonary disease Source: Annual Congress 2012 - Asthma and COPD: understanding through mechanisms Year: 2012
MiR-320c regulates SERPINA1 expression and is associated with pulmonary disease in alpha-1-antitrypsin deficiency Source: International Congress 2016 – How the understanding og molecular and genomic crosstalk is helping to diagnose lung disease Year: 2016
Increased CTGF expression of circulating fibrocytes in asthmatic patients with severe OSA - the role of HIF-1a and HDAC7 Source: International Congress 2018 – New kids on the block: novel molecular pathways and therapeutic targets in chronic lung diseases Year: 2018
The role of matrix metalloproteinases in cystic fibrosis lung disease Source: Eur Respir J 2011; 38: 721-727 Year: 2011